Crystal Banh

Ms. Crystal Banh


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
CBCrystal Banh
Crystal Banh
Aleksandar Z. SičAleksandar Z. Sič
Aleksandar Z. Sič
Nebojsa Nick KnezevicNebojsa Nick Knezevic
Nebojsa Nick Knezevic

20 July 2025 in Cells
Verified
Journal Article
Open access
PDF file
Aarish ManzarAarish Manzar
Aarish Manzar
Aleksandar Z. SičAleksandar Z. Sič
Aleksandar Z. Sič
CBCrystal Banh
Crystal Banh
Nebojsa Nick KnezevicNebojsa Nick Knezevic
Nebojsa Nick Knezevic
Calcium channel blockers (CCBs), originally developed for cardiovascular indications, have gained attention for their therapeutic potential in neuropsychiatric, endocrine, and pain-related disorders. In neuropsychiatry, nimodipine and isradipine, both L-type CCBs, show mood-stabilizing and neuroprotective effects, with possible benefits in depression, bipolar disorder, and schizophrenia. In endocrinology, verapamil, a non-dihydropyridine L-type blocker, has been associated with the preservation of pancreatic β-cell function and reduced insulin dependence in diabetes. CCBs may also aid in managing primary aldosteronism and pheochromocytoma, particularly in patients with calcium signaling mutations. In pain medicine, α2δ ligands and selective blockers of N-type and T-type channels demonstrate efficacy in neuropathic and inflammatory pain. However, their broader use is limited by challenges in central nervous system (CNS) penetration, off-target effects, and heterogeneous trial outcomes. Future research should focus on pharmacogenetic stratification, novel delivery platforms, and combination strategies to optimize repurposing of CCBs across disciplines.